FI101476B1 - Menetelmä kalsiumista riippuvan proteiini C:n vastaisen monoklonaalisen vasta-aineen valmistamiseksi - Google Patents

Menetelmä kalsiumista riippuvan proteiini C:n vastaisen monoklonaalisen vasta-aineen valmistamiseksi

Info

Publication number
FI101476B1
FI101476B1 FI904262A FI904262A FI101476B1 FI 101476 B1 FI101476 B1 FI 101476B1 FI 904262 A FI904262 A FI 904262A FI 904262 A FI904262 A FI 904262A FI 101476 B1 FI101476 B1 FI 101476B1
Authority
FI
Finland
Prior art keywords
protein
antibody
activation
isolation
monoclonal antibody
Prior art date
Application number
FI904262A
Other languages
English (en)
Swedish (sv)
Other versions
FI904262A0 (fi
FI101476B (fi
Inventor
Charles T Esmon
Naomi L Esmon
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Publication of FI904262A0 publication Critical patent/FI904262A0/fi
Application granted granted Critical
Publication of FI101476B publication Critical patent/FI101476B/fi
Publication of FI101476B1 publication Critical patent/FI101476B1/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04Phospholipids, i.e. phosphoglycerides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI904262A 1988-12-30 1990-08-29 Menetelmä kalsiumista riippuvan proteiini C:n vastaisen monoklonaalisen vasta-aineen valmistamiseksi FI101476B1 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29244788A 1988-12-30 1988-12-30
US29244788 1988-12-30
US8905851 1989-12-28
PCT/US1989/005851 WO1990007524A1 (en) 1988-12-30 1989-12-28 Monoclonal antibody against protein c

Publications (3)

Publication Number Publication Date
FI904262A0 FI904262A0 (fi) 1990-08-29
FI101476B FI101476B (fi) 1998-06-30
FI101476B1 true FI101476B1 (fi) 1998-06-30

Family

ID=23124711

Family Applications (1)

Application Number Title Priority Date Filing Date
FI904262A FI101476B1 (fi) 1988-12-30 1990-08-29 Menetelmä kalsiumista riippuvan proteiini C:n vastaisen monoklonaalisen vasta-aineen valmistamiseksi

Country Status (11)

Country Link
EP (1) EP0407544B1 (fi)
JP (1) JP2559537B2 (fi)
KR (1) KR940002033B1 (fi)
AT (1) ATE122057T1 (fi)
AU (2) AU641634B2 (fi)
CA (1) CA2006684C (fi)
DE (1) DE68922491T2 (fi)
DK (1) DK171826B1 (fi)
ES (1) ES2074562T3 (fi)
FI (1) FI101476B1 (fi)
WO (1) WO1990007524A1 (fi)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
AU4784693A (en) * 1992-07-24 1994-02-14 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
WO1994005692A1 (en) * 1992-08-27 1994-03-17 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5532136A (en) * 1993-06-22 1996-07-02 Bionebraska, Inc. Monoclonal antibody assay and kit for detecting metal cations in body fluids
AU688778B2 (en) * 1993-07-09 1998-03-19 Avant Immunotherapeutics, Inc. Protein purification
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
ATE410514T1 (de) * 1994-06-10 2008-10-15 Oklahoma Med Res Found Calciumbindende rekombinante antikörper gegen protein c
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI654203B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TWI673063B (zh) * 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白c抗體之出血性疾病的治療
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
EP3574010A4 (en) 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE

Also Published As

Publication number Publication date
KR940002033B1 (ko) 1994-03-14
CA2006684A1 (en) 1990-06-30
ATE122057T1 (de) 1995-05-15
DK209090D0 (da) 1990-08-30
DK171826B1 (da) 1997-06-23
AU4422893A (en) 1994-01-27
DE68922491T2 (de) 1995-11-09
AU4968390A (en) 1990-08-01
WO1990007524A1 (en) 1990-07-12
FI904262A0 (fi) 1990-08-29
ES2074562T3 (es) 1995-09-16
KR910700266A (ko) 1991-03-14
EP0407544A1 (en) 1991-01-16
JPH03504332A (ja) 1991-09-26
DK209090A (da) 1990-08-30
AU641634B2 (en) 1993-09-30
FI101476B (fi) 1998-06-30
JP2559537B2 (ja) 1996-12-04
EP0407544B1 (en) 1995-05-03
DE68922491D1 (de) 1995-06-08
AU669540B2 (en) 1996-06-13
CA2006684C (en) 1996-12-17

Similar Documents

Publication Publication Date Title
FI101476B1 (fi) Menetelmä kalsiumista riippuvan proteiini C:n vastaisen monoklonaalisen vasta-aineen valmistamiseksi
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
RU94045919A (ru) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
EP0930366A3 (en) Binding domains in delta proteins
JPH03503118A (ja) ヒト インターロイキン4に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
DE69435020D1 (en) Protein-tyrosin-phosphatase ptp-s31
KR870001311A (ko) 단백질 및 폴리펩티드의 제조 방법
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
ATE208815T1 (de) Genetisches igfbp-5 rodierendes material
Baker et al. Effect of protease inhibitors and substrates on deoxycorticosterone binding to its receptor in dog MDCK kidney cells
Abraha et al. The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits
Barnes et al. Glass-bead affinity chromatography of cell attachment and spreading-promoting factors of human serum
Kosaka et al. Hyperviscosity syndrome associated with an idiopathic monoclonal IgA-rheumatoid factor
DE69316388T2 (de) CRF Bindungsproteine
Woodley et al. Specific identification of tissue kallikrein in exocrine tissues and in cell-free translation products with monoclonal antibodies
Arlaud et al. Use of an IgG fragment prepared with particulate plasmin to study the C1 binding and activation
Solomon et al. Affinity purification of antibodies using immobilized FB domain of protein A
Zibirre et al. Detection and localization of a cytoplasmic domain on the beta-subunit of Na+, K+-ATPase. A monoclonal antibody study.
Werrbach-Perez et al. De novo synthesis of NGF subunits in S-180 mouse sarcoma cell line
NO903788L (no) Monoklonalt antistoff mot protein c.
Fassina Protein A Mimetic (PAM) Affinity Chromatography: Immunoglobulins Purification
Mannhalter Purification of plasma protein
Yasuda et al. Use of antibodies against synthetic peptides for analysis of molecular multiplicity: human deoxyribonuclease I polymorphism
Michiyo et al. Functional properties of the allotypes of mouse complement regulatory protein, factor H: difference of compatibility of each allotype with human factor I
Ikura et al. Monoclonal antibody to noncatalytic subunit of bovine plasma factor XIII: selective isolation of catalytic subunit

Legal Events

Date Code Title Description
FG Patent granted

Owner name: OKLAHOMA MEDICAL RESEARCH FOUNDATION